JP2011525174A5 - - Google Patents

Download PDF

Info

Publication number
JP2011525174A5
JP2011525174A5 JP2011511802A JP2011511802A JP2011525174A5 JP 2011525174 A5 JP2011525174 A5 JP 2011525174A5 JP 2011511802 A JP2011511802 A JP 2011511802A JP 2011511802 A JP2011511802 A JP 2011511802A JP 2011525174 A5 JP2011525174 A5 JP 2011525174A5
Authority
JP
Japan
Prior art keywords
kinesin
hset
meiotic
activity
meiotic kinesin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011511802A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011525174A (ja
JP5735417B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/045406 external-priority patent/WO2009155025A1/en
Publication of JP2011525174A publication Critical patent/JP2011525174A/ja
Publication of JP2011525174A5 publication Critical patent/JP2011525174A5/ja
Application granted granted Critical
Publication of JP5735417B2 publication Critical patent/JP5735417B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011511802A 2008-05-30 2009-05-28 減数分裂期キネシンに関連する疾患を治療する方法 Expired - Fee Related JP5735417B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5759008P 2008-05-30 2008-05-30
US61/057,590 2008-05-30
PCT/US2009/045406 WO2009155025A1 (en) 2008-05-30 2009-05-28 Methods of treating a meiotic kinesin-associated disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015020184A Division JP6132409B2 (ja) 2008-05-30 2015-02-04 減数分裂期キネシンに関連する疾患を治療する方法

Publications (3)

Publication Number Publication Date
JP2011525174A JP2011525174A (ja) 2011-09-15
JP2011525174A5 true JP2011525174A5 (https=) 2012-07-12
JP5735417B2 JP5735417B2 (ja) 2015-06-17

Family

ID=41110533

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2011511802A Expired - Fee Related JP5735417B2 (ja) 2008-05-30 2009-05-28 減数分裂期キネシンに関連する疾患を治療する方法
JP2015020184A Expired - Fee Related JP6132409B2 (ja) 2008-05-30 2015-02-04 減数分裂期キネシンに関連する疾患を治療する方法
JP2016108400A Expired - Fee Related JP6184556B2 (ja) 2008-05-30 2016-05-31 減数分裂期キネシンに関連する疾患を治療する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015020184A Expired - Fee Related JP6132409B2 (ja) 2008-05-30 2015-02-04 減数分裂期キネシンに関連する疾患を治療する方法
JP2016108400A Expired - Fee Related JP6184556B2 (ja) 2008-05-30 2016-05-31 減数分裂期キネシンに関連する疾患を治療する方法

Country Status (12)

Country Link
US (3) US8629118B2 (https=)
EP (1) EP2315594B1 (https=)
JP (3) JP5735417B2 (https=)
KR (1) KR20110022000A (https=)
CN (1) CN102316877A (https=)
AU (1) AU2009260527A1 (https=)
BR (1) BRPI0912043A2 (https=)
CA (1) CA2725911A1 (https=)
EA (1) EA201071422A1 (https=)
ES (1) ES2633930T3 (https=)
MX (1) MX2010012931A (https=)
WO (1) WO2009155025A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9486449B2 (en) 2007-10-09 2016-11-08 Malka COHEN-ARMON Cancer therapy
CN102316877A (zh) 2008-05-30 2012-01-11 达那-法伯癌症研究所 治疗减数分裂驱动蛋白相关疾病的方法
US20150087687A1 (en) 2012-03-23 2015-03-26 Dennis Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
US20150309031A2 (en) * 2013-12-05 2015-10-29 Novazoi Theranostics Compositions and methods for prognosis and treatment of cancer
US9589100B2 (en) * 2014-02-28 2017-03-07 Novazoi Theranostics Method for determining the risk profile of neoplastic tissue
CN113456633A (zh) * 2021-06-11 2021-10-01 广西医科大学 红海海绵素a在制备抗肺癌侵袭转移药物中的应用
WO2023131690A1 (en) 2022-01-10 2023-07-13 Merck Patent Gmbh Substituted heterocycles as hset inhibitors
CN115327125A (zh) * 2022-07-14 2022-11-11 宁波大学 一种蛋白质inf2在制备肝癌诊断标志物中的应用
CN120265629A (zh) 2022-11-07 2025-07-04 默克专利股份公司 被取代的双环和三环hset抑制剂

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US6410254B1 (en) * 1999-05-18 2002-06-25 Cytokinetics Compositions and assays utilizing ADP or phosphate for detecting protein modulators
WO2000063353A1 (en) * 1999-04-20 2000-10-26 Cytokinetics Human kinesins and methods of producing and purifying human kinesins
US6743599B1 (en) * 1999-05-18 2004-06-01 Cytokinetics, Inc. Compositions and assays utilizing ADP or phosphate for detecting protein modulators
US7202051B1 (en) * 1999-05-18 2007-04-10 Cytokinetics, Inc. Compositions and assays utilizing ADP or phosphate for detecting protein modulators
US7416856B2 (en) * 1999-05-18 2008-08-26 Cytokinetics, Inc. High sensitivity assay for detection of nucleoside diphosphate production
IL158083A0 (en) 2001-03-29 2004-03-28 Bristol Myers Squibb Co A PHARMACEUTICAL COMPOSITION CONTAINING AN Eg5 PROTEIN INHIBITOR
US20040009156A1 (en) 2001-10-12 2004-01-15 Christoph Reinhard Antisense therapy using oligonucleotides that target human kinesin genes for treatment of cancer
US7163927B2 (en) 2002-05-23 2007-01-16 Isis Pharmaceuticals, Inc. Antisense modulation of kinesin-like 1 expression
US20050100508A1 (en) * 2003-11-12 2005-05-12 Nichols M. J. Methods for identifying drug combinations for the treatment of proliferative diseases
US20070026424A1 (en) 2005-04-15 2007-02-01 Powell Charles A Gene profiles correlating with histology and prognosis
AR062200A1 (es) 2006-08-04 2008-10-22 Aeterna Zentaris Gmbh Derivados de antraceno y su uso para el tratamiento de emfermedades tumorales bengnas y malingnas
US20080051463A1 (en) * 2006-08-04 2008-02-28 Aeterna Zentaris Gmbh Anthracene compounds and their use for treating benign and malignant tumor disorders
US20100145131A1 (en) 2007-05-01 2010-06-10 Helena Grinberg-Rashi Methods and kits for predicting cancer metastasis
CN102316877A (zh) 2008-05-30 2012-01-11 达那-法伯癌症研究所 治疗减数分裂驱动蛋白相关疾病的方法

Similar Documents

Publication Publication Date Title
JP2011525174A5 (https=)
Bates et al. Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T‐cell lymphoma
Quint et al. The role of sphingosine kinase isoforms and receptors S1P1, S1P2, S1P3, and S1P5 in primary, secondary, and recurrent glioblastomas
Chan et al. RETRACTED ARTICLE: Belinostat and panobinostat (HDACI): in vitro and in vivo studies in thyroid cancer
Liu et al. Calpain/SHP-1 interaction by honokiol dampening peritoneal dissemination of gastric cancer in nu/nu mice
An et al. Metformin inhibits proliferation and growth hormone secretion of GH3 pituitary adenoma cells
US12590162B2 (en) Cancer treatment
BR112019026484A2 (pt) tinostamustina para uso no tratamento de leucemia prolinfocítica de células t
Li et al. Curcumin suppresses the progression of gastric cancer by regulating circ_0056618/miR-194-5p axis
EP2945646A1 (en) Estrogen receptor inhibitors
Lee et al. Targeting PI3K/mTOR signaling exerts potent antitumor activity in pheochromocytoma in vivo
WO2019204399A1 (en) Methods and compositions for treating cancer
Fu et al. Avenanthramide A potentiates Bim-mediated antineoplastic properties of 5-fluorouracil via targeting KDM4C/MIR17HG/GSK-3β negative feedback loop in colorectal cancer
KR20220035275A (ko) 다발성 골수종 치료
Tellenbach et al. Combination of the novel RAF dimer inhibitor brimarafenib with the MEK inhibitor mirdametinib is effective against NRAS mutant melanoma
KR101999476B1 (ko) Alk 저해제에 내성을 획득한 eml4-alk 양성 비소세포폐암의 치료를 위한 약물 선택의 정보 제공 방법
Cai et al. mTORC1 hyperactivation and resultant suppression of macroautophagy contribute to the induction of cardiomyocyte necroptosis by catecholamine surges
CN114599638B (zh) 小分子肝x受体调节剂及其用途
US20170027955A1 (en) Expression levels of bcl-xl, bcl2, bcl-w, and bad and cancer therapies
Wu et al. Adiponectin signals through Adiponectin Receptor 1 to reverse imatinib resistance in K562 human chronic myeloid leukemia cells
TWI522616B (zh) 抗癌藥物之篩選方法及治療癌症之方法
US20220202804A1 (en) Compositions and methods to treat cancer
Wang et al. BAP1 suppresses white adipose tissue browning and thermogenesis through deubiquitinating KDM1B
WO2024254195A1 (en) Methods for treating pancreatic cancer with a combination of des-methyl pateamine a and a class 1 hdac inhibitor
WO2025189122A1 (en) Method to prevent and treat cancer cachexia